Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNETISMM-1: Elranatamab in RRMM
NCT03269136Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2017
- Primary completion
- Jan 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of elranatamab in multiple myeloma (MM) (4 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicities, Objective Response Rate up to 34.3 months and 1 more. Started Nov 2017; status: completed.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03269136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03269136.